FENC
FENNEC PHARMACEUTICALS INC.
Next earnings Aug 12, 2026 · consensus $0.01 EPS, $16.4M rev
$11.02
▲ +4.46%$11.02▲ +42.01%
over 1Y
L $5.77EODHDH $11.02
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.5%
1W+15.6%
1M+10.5%
3M+86.5%
YTD+43.5%
1Y+42.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Conservative balance sheet (liabilities/equity 0.99x); but revenue declined -6.1% YoY.
FENNEC PHARMACEUTICALS INC. shows $44.6M in FY2025 revenue (-6.1% YoY), a -21.8% net margin, and -27.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $1.53M | $21.3M | $47.5M | $44.6M |
| Gross profit | — | $1.45M | $20.0M | — | — |
| Operating income | -$17.2M | -$22.6M | -$12.8M | $2.57M | -$6.28M |
| Net income | -$17.3M | -$23.7M | -$16.0M | -$436K | -$9.74M |
| Diluted EPS | -$0.67 | -$0.90 | -$0.60 | -$0.02 | -$0.34 |
| Net margin | — | -1544.9% | -75.5% | -0.9% | -21.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$362M
EV / EBITDA—
EV / Sales8.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.6%
FCF yield-3.3%
Quality & risk
ROIC (est.)-9.1%
Free cash flow-$12.5M
Total debt$19.3M
Net cash$17.4M
Altman Z-Score3.25 safe
Piotroski F-Score2/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+24.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗S-8Filing2026-06-11open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗8-KPeriod ending 2026-06-102026-06-10open ↗4Period ending 2026-05-312026-06-02open ↗144Filing2026-06-01open ↗4Period ending 2026-05-312026-06-01open ↗4Period ending 2026-05-312026-06-01open ↗4Period ending 2026-05-312026-06-01open ↗4Period ending 2026-05-312026-06-01open ↗
Frequently asked
- Is FENNEC PHARMACEUTICALS INC. (FENC) a buy?
- FENC currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.99x); but revenue declined -6.1% YoY.
- What is FENNEC PHARMACEUTICALS INC.'s quality score?
- FENC scores 36.05882352941176/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001211583, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:37:19 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.